Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LLSDP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
9MW2921
|
|||||
| Synonyms |
9MW2921
Click to Show/Hide
|
|||||
| Organization |
Mabwell Bioscience (Originator)
|
|||||
| Drug Status |
Phase 1/2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Anti-TROP2 antibody
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
Mtoxin
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
2027 Update
The indication landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: Age 18-75; ECOG 0-1; histologically confirmed advanced/metastatic malignancies refractory to standard therapy; ≥1 measurable lesion; adequate organ function; provision of tumor samples (≥5 slides); negative pregnancy test; commitment to contraception (6 months post-treatment); protocol compliance capability. Survival expectancy ≥3 months.
Click to Show/Hide
|
||||
| Administration Dosage |
All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05990452 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase I/II First-in-human Study of 9MW2921 to Evaluate the Safety, Tolerability and Preliminary Efficacy of 9MW2921 in Patients With Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary endpoints include DLT assessment (21 days post-first dose), AE/SAE incidence (up to 2 years), and ORR (CR+PR rate per RECIST 1.1, monitored for 2 years or until treatment discontinuation).
|
||||
| Other Endpoint |
Secondary endpoints comprise PK parameters (Cmax/AUC/t½ over 1 year), ADA development (2 years), and efficacy measures (PFS/DoR/DCR per RECIST 1.1, tracked for 2 years or until progression/death).
|
||||